Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.

Corresponding Author: Joseph F. Levy, PhD, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 1812 Ashland Ave, Baltimore, MD 21043 (jlevy@jhu.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.